1. Estate Grant (Luther Allyn Shourds Dean
Bequest), 2013-2015
"Impacts of environmental toxicity on children and
across the lifespan"
2. Dwoskin Foundation through the American
Foundation for UBC, 2011-2016
"Aluminum vaccine adjuvants and neurodevelopment outcomes in an
animal model of autism spectum disorder"
3. Katlyn Fox Foundation, 2010-2016
"Neurotoxic impacts of aluminum in CNS "
4. Lotus Foundation through the American
foundation for UBC , 2011-2012
"The toxicity of polysorbate 80, sodium borate, and aluminum at
clinically relevant concentrations in an in vivo animal model"
5. ALS SC Bernice Ramsay Discovery Grant ,
2010-2011
"Progranulin as a novel therapeutic for motor neuron
rescue in an animal model of ALS"
6. Scottish Rite Charitable Foundation
(SRCF), 2007-2010
"Neurobiological basis of cycad toxicity in a mouse
model of ALS-PDC"
7. Pacific Alzheimer’s Research
Foundation, 2007-2009
"Role of progranulin in brain function and
neuroprotection"
8. NIH (USA), R03, 2007-2008
"Neurotoxicity of sterol glucosides: role in
ALS-PDC"
9. NIH, NINDS (USA), R01, 2006-2011
"Time-lines of neural degeneration in ALS-PDC mouse
model"
10. Amyotrophic Lateral Sclerosis
Association (USA), 2006-2009
"Roles of sterol glucoside neurotoxicity in
ALS-PDC"
11. Parkinson’s Disease Foundation,
2005-2007
"Cycad and sterol glucoside neurotoxicity in vivo and
in vitro models"
12. U.S. Department of Defense (Army Medical
Research Acquisition Activity), 2002-2007
"Implications of Cycad Neurotoxicity for
ALS-PDC"
13. Natural Sciences and Engineering
Research Council of Canada (NSERC), 2001-2005
"Genetic Propensity for Cycad Neurotoxicity in a
Murine Model of Neurological Disease"
14. Amytrophic Lateral Sclerosis Association
(ALSA), 2001-2003
"Cycad Sterol Glucoside Toxicity and ALS-PDC:
Implications for the Etiology of ALSO"
15. Parkinson's Disease Foundation, 2002
"Neural Stem Cell Injections as a Potential Therapy
for Cycad-induced Neurodegeneration"
16. Scottish Rite Charitable Foundation
(SRCF), 1999-2003
"Estrogen & Apolipoprotein E as therapies for
neurodegenerative disease"
